Novartis | NOVN - Trade Debtors


Novartis reported $9.85B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Alcon AG USD 2.1B 90M Jun/2026
Almirall EUR 196.15M 20.22M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
Autolus Therapeutics Ltd USD 38.07M 37.71M Mar/2026
Bayer EUR 18.7B 146M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Fresenius EUR 4.64B 862M Jun/2026
Fresenius Medical Care EUR 3.47B 250.22M Jun/2026
Genmab DKK 1.22B 192M Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
GRIFOLS EUR 1.19B 231M Jun/2026
Hikma Pharmaceutical USD 1.08B 27M Dec/2025
J&J USD 22.54B 1.21B Mar/2026
Lakefront Biotherapeutics EUR 149.47M 95.44M Jun/2026
Lonza CHF 1.78B 55M Dec/2025
Merck EUR 4.95B 139M Jun/2026
Merck USD 12.21B 435M Mar/2026
Novartis USD 9.85B 252M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Novo Nordisk DKK 114.94B 8.68B Jun/2026
Orion EUR 543.8M 155.8M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Philips EUR 3.6B 70M Jun/2026
Recordati EUR 778.71M 13.98M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sanofi EUR 492M 10M Jun/2026
UCB EUR 1.97B 54M Dec/2025